Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma

J Asthma Allergy. 2021 Jun 25:14:713-725. doi: 10.2147/JAA.S305513. eCollection 2021.

Abstract

Background: Health-related quality of life (HRQoL) and productivity of patients with confirmed severe asthma (SA) have not been well characterized in large, real-world populations.

Purpose: To characterize SA impact on HRQoL, work productivity, and activity impairment in a large, real-world cohort in the United States (US).

Methods: CHRONICLE is an observational study of specialist-treated adults (≥18 years) in the US with SA receiving biologics or maintenance systemic corticosteroids (mSCS), or those persistently uncontrolled by high-dosage inhaled corticosteroids with additional controllers (HD ICS+). At enrollment, patients completed the St. George's Respiratory Questionnaire (SGRQ) and Work Productivity and Activity Impairment (WPAI) questionnaire. Results were analyzed for those enrolled between February 2018 and February 2020.

Results: Among patients who completed enrollment questionnaires (n = 1109), mean age was 54 years and most were women (70%). Among SGRQ respondents (n = 960), mean (SD) total score was 43 (23); 51% reported good/very good health. Among WPAI respondents (n = 1057; 566 employed), mean (SD) overall work impairment was 21% (25). Patients receiving biologics (vs mSCS, HD ICS+ only) had better SGRQ total scores (38 vs 59, 48) and lower work impairment (17% vs 34%, 27%). Patients with better SGRQ activity scores relative to symptom scores had better SGRQ impacts scores, total scores, and reported better overall health.

Conclusion: SA significantly affects HRQoL, work productivity, and activity. The SGRQ is a valuable research instrument for evaluating HRQoL in SA. Due to its association with HRQoL and overall health, activity impairment should be a focus when monitoring patients' disease control.

Study registration: ClinicalTrials.gov Identifier: NCT03373045.

Keywords: SGRQ; WPAI; activity; real-world, St. George’s Respiratory Questionnaire; symptoms.

Associated data

  • ClinicalTrials.gov/NCT03373045

Grants and funding

This work was supported by and the CHRONICLE study is funded by AstraZeneca. Four named authors are employees of AstraZeneca; therefore, AstraZeneca was involved in the study design, collection, analysis, and interpretation of data and the development and review of the manuscript. The decision to submit the manuscript for publication was made by the authors.